Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06965504 · ClinicalTrials.gov registry record · NA
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
A NA study, sponsored by Abiomed.
- Not yet
- Registry status
- NA
- Development phase
- 250
- Enrollment target
NCT06965504 is a NA study that has not yet begun recruiting, run by Abiomed. The registered enrollment target is 250 participants.
The verdict
NCT06965504, a NA study, has not yet begun recruiting, sponsored by Abiomed.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
Study Summary
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
Interventions
- DEVICE Impella 5.5 SmartAssist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2029-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06965504
The ClinicalTrials.gov registry entry for NCT06965504 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abiomed, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Impella 5.5 SmartAssist is the first listed.
NCT06965504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06965504 about?
NCT06965504 is a clinical study titled "INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery". The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
What is the current status of trial NCT06965504?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2026-04-01. Estimated completion is 2029-06-01.
What interventions are being tested in trial NCT06965504?
The interventions under investigation include: Impella 5.5 SmartAssist (DEVICE).
Who is sponsoring clinical trial NCT06965504?
This trial is sponsored by Abiomed, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.